10-Q: Agilon Health Reports Q3 Losses Amid Membership Decline

Agilon Health reported a net loss of $110 million in Q3 2025, with declining Medicare Advantage membership and significant year-to-date financial deterioration.

Summary

• Net loss for the three months ended September 30, 2025, was $110.2 million, an improvement from a net loss of $117.6 million in the same period of 2024.
• Year-to-date net loss for the nine months ended September 30, 2025, worsened to $202.5 million, compared to a net loss of $154.3 million in the prior year period.
• Total revenues decreased by 1% to $1.44 billion for Q3 2025 and by 4% to $4.36 billion for the nine months ended September 30, 2025, primarily due to declines in average membership and lower risk adjustment revenue.
• Medicare Advantage (MA) members decreased by 4% to approximately 502,800 as of September 30, 2025, compared to September 30, 2024.
• CMS ACO Models attributed beneficiaries decreased by 13% to approximately 115,300 as of September 30, 2025.
• Gross profit remained negative at $67.6 million for Q3 2025, worsening from a negative $64.2 million in Q3 2024. Year-to-date gross profit significantly declined from a positive $43.1 million in 2024 to a negative $69.4 million in 2025.
• Medical margin, a non-GAAP measure, showed an improved loss of $57.0 million for Q3 2025 compared to a loss of $58.3 million in Q3 2024. However, year-to-date medical margin decreased by 91% to $17.8 million from $204.6 million in 2024.
• Adjusted EBITDA loss, a non-GAAP measure, improved to $91.5 million for Q3 2025 from a loss of $96.5 million in Q3 2024. Year-to-date Adjusted EBITDA loss worsened to $154.3 million from a loss of $70.2 million in 2024.
• Cash and cash equivalents decreased to $171.7 million as of September 30, 2025, from $188.2 million at December 31, 2024.
• Net cash used in operating activities increased to $85.2 million for the nine months ended September 30, 2025, compared to $74.2 million in the prior year period.
• The company recognized a $14.0 million gain from discontinued operations for the nine months ended September 30, 2025, related to the release of a contingent obligation from its former Hawaii operations.

Sentiment

Score: 3

Explanation: The overall sentiment is negative due to significant year-to-date financial deterioration across key metrics (net loss, gross profit, medical margin, Adjusted EBITDA), declining membership, and increased cash burn from operations. While Q3 showed some sequential improvements in net loss and Adjusted EBITDA loss, the company's forward-looking statements indicate continued losses and a potential need for future capital, highlighting ongoing operational and financial challenges.

Positives

• Net loss for Q3 2025 improved to $110.2 million from $117.6 million in Q3 2024.
• Adjusted EBITDA loss for Q3 2025 improved to $91.5 million from $96.5 million in Q3 2024.
• General and administrative expenses decreased by 11% in Q3 2025 and 15% year-to-date, driven by lower platform support costs, reduced geography entry investments, and decreased stock-based compensation.
• Income from equity method investments increased significantly by 542% in Q3 2025 and 77% year-to-date, primarily from CMS ACO Models investments due to higher medical margin and the exit of underperforming partners.
• A $14.0 million gain was recognized from discontinued operations year-to-date 2025, related to the release of a contingent obligation from the Hawaii operations divestiture.

Negatives

• Total revenues decreased by 1% in Q3 2025 and 4% year-to-date, primarily due to declining average membership and lower risk adjustment revenue.
• Medicare Advantage members decreased by 4% and CMS ACO Models beneficiaries decreased by 13% as of September 30, 2025, compared to the prior year.
• Year-to-date net loss worsened to $202.5 million in 2025 from $154.3 million in 2024.
• Year-to-date gross profit significantly declined from a positive $43.1 million in 2024 to a negative $69.4 million in 2025.
• Year-to-date medical margin decreased by 91% to $17.8 million from $204.6 million in 2024.
• Year-to-date Adjusted EBITDA loss worsened to $154.3 million from $70.2 million in 2024.
• Average medical services expense per member increased by 4% in Q3 2025 and 5% year-to-date, primarily due to elevated medical cost trends.
• Medical claims and related payables increased to $1.06 billion as of September 30, 2025, from $931.7 million at December 31, 2024.
• Net cash used in operating activities increased by 15% to $85.2 million for the nine months ended September 30, 2025, indicating increased cash burn.
• The company expects to continue incurring operating losses and negative cash flows for the foreseeable future.

Risks

• History of net losses and expectation that expenses will increase in the future.
• Failure to identify and develop successful new geographies, physician partners, and payors, or execute upon growth initiatives.
• Medical expenses incurred on behalf of members may exceed revenues received.
• Ability to maintain and secure additional contracts with Medicare Advantage (MA) payors on favorable terms.
• Ability to grow new physician partner relationships sufficient to recover startup costs.
• Availability of additional capital, on acceptable terms or at all, to support the business in the future.
• Significant reduction in membership.
• Inaccuracy in estimates of members' risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts.
• Reliance on a limited number of key payors.
• The limited terms of contracts with payors and the ability to renew them upon expiration.
• Impact of changes to, and dependence on, federal government healthcare programs.
• Uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures.
• Lawsuits not covered by insurance and securities class action litigation.
• Risks related to management transitions, including the search for a permanent Chief Executive Officer, and the ability to effectively manage leadership changes.

Future Outlook

The company expects to continue incurring operating losses and generating negative cash flows from operations for the foreseeable future due to ongoing investments in business expansion and additional general and administrative costs related to operating as a public company. It may require additional capital resources in the future to fund strategic initiatives.

Management Comments

• Our business is transforming healthcare by empowering the primary care physicians (PCPs) to be the agent for change in the communities they serve.
• We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost, and patient experience when provided with the right infrastructure and payment model.
• Our goal is to remove the barriers that prevent community-based physicians from evolving to a Total Care Model, where the physician is empowered to manage health outcomes and the total healthcare needs of their attributed Medicare patients.

Industry Context

Agilon Health operates within the evolving U.S. healthcare landscape, specifically focusing on Medicare Advantage and CMS ACO Models. Its strategy of empowering primary care physicians through a globally capitated, value-based care model aligns with broader industry trends aimed at improving patient outcomes and controlling costs. The reported elevated medical cost trends reflect a challenge faced across the healthcare sector, impacting profitability for risk-bearing entities.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• In re agilon health, inc. Securities Litigation: A consolidated class action lawsuit asserting securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act and Sections 11, 12(a)(2) and 15 of the Securities Act, related to financial guidance, medical margin, Adjusted EBITDA, growth strategy, and data management. Some claims were dismissed, others are proceeding to discovery.
• In Re agilon health, inc. Shareholder Derivative Litigation: Consolidated putative stockholder derivative class action lawsuits (Douglas v. Steven J. Sell et al. and Bingham v. Steven J. Sell et al.) asserting claims under Sections 14(a) and 10(b) of the Exchange Act, and common law claims including breach of fiduciary duty. These matters are currently stayed during the discovery period for the Consolidated Securities Matter.
• Bushansky v. Steven J. Sell et al.: A third putative stockholder derivative class action lawsuit filed in federal court in Ohio with substantially the same allegations as the Derivative Matters. The company plans to file a motion to transfer this matter to Texas for consolidation.

Related Party Transactions

• The company's largest shareholder is an investment fund associated with Clayton Dubilier & Rice, LLC (CD&R), a private equity firm, and all funds affiliated with CD&R are considered related parties. No specific related party transactions beyond this general statement were detailed in the filing.

Stakeholder Impact

• Shareholders: Face potential dilution from future capital raises, continued net losses, and stock price volatility due to ongoing financial and legal challenges.
• Employees: Affected by strategic changes in the workforce, as indicated by severance costs related to the former CEO's departure and other workforce adjustments.
• Physician Partners: Their compensation is tied to a base rate and a share in savings, which is impacted by losses generated in partnerships and geographies.
• Customers (Medicare Advantage members): Experience changes in care provision due to membership declines and market exits, though the company aims to improve health outcomes through its Total Care Model.
• Creditors: The company's Credit Facility matures in February 2026, and while currently in compliance with covenants, ongoing losses and potential capital needs could impact future creditworthiness.

Next Steps

• Continue the process of onboarding payors onto the new payor data pipeline (the Model) implemented in Q1 2025.
• Monitor developments and evaluate any potential future impacts of the One Big Beautiful Bill Act on the company's effective tax rate.
• Evaluate the potential impact of adopting new accounting standards, ASU 2024-03 and ASU 2025-01, on disclosures.
• File a motion to transfer the Bushansky v. Steven J. Sell et al. lawsuit to Texas to be consolidated with the pending Derivative Matters.

Key Dates

Recommendation

The company continues to report substantial net losses and negative cash flows from operations, with a significant deterioration in year-to-date gross profit, medical margin, and Adjusted EBITDA. Declining Medicare Advantage membership and elevated medical cost trends pose ongoing challenges. While Q3 showed some sequential improvement in net loss and Adjusted EBITDA loss, the overall financial trajectory and the expectation of continued losses, coupled with ongoing litigation and the need for potential future capital, suggest a high-risk profile. The upcoming maturity of the Credit Facility in February 2026 also adds to the financial uncertainty. These factors indicate a challenging environment for sustained profitability and growth, warranting a 'sell' recommendation for risk-averse investors.

Keywords

agilon health, AGL, healthcare, Medicare Advantage, ACO REACH, CMS, capitation, physician groups, financial results, Q3 2025, 10-Q, net loss, medical margin, Adjusted EBITDA, value-based care, medical costs